Vita 34 becomes market leader in Austria
Vita 34 AG / Key word(s): Acquisition 01.12.2014 18:24 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Vita 34 becomes market leader in Austria Leipzig, 1 December 2014 - Vita 34 AG (WKN A0BL84) takes over the commercial operations of the Austrian market leader for umbilical cord blood storages as of January 2, 2015 within the framework of an asset deal. Today, the board of directors signed the purchase agreement to take over all the assets of Vivocell Biosolutions GmbH & Co KG from Graz at a price of 650,000 Euro upon approval by the supervisory board. The 13,000 stored preparations that were taken over will be taken care of in the future by the Austrian subsidiary of Vita 34 AG. There will be no transfer of Vivocell's employees to Vita 34. The group revenue of Vita 34 will increase in 2015 by about seven percent because of the takeover. Additional information: ISIN: DE000A0BL849 WKN: A0BL84 Ticker symbol: V3V Market segment: Regulated Market (Prime Standard) of the Frankfurt Stock Exchange Vita 34 AG Deutscher Platz 5 04103 Leipzig Germany END OF THE AD-HOC NOTICE 01.12.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: ir@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------